about
Optimal duration of a first-line palliative chemotherapy in disseminated colorectal cancer - a review of the literature from a developing country perspectiveOverexpression of 5-lipoxygenase in sporadic colonic adenomas and a possible new aspect of colon carcinogenesis.Thymidylate synthase gene polymorphism and survival of colorectal cancer patients receiving adjuvant 5-fluorouracil.Prevalence of Cryptosporidium sp. in patients with colorectal cancer.Thymidylate synthase expression and p21(WAF1)/p53 phenotype of colon cancers identify patients who may benefit from 5-fluorouracil based therapy.Colorectal cancer and Cryptosporidium spp. infection.The Influence Of Obesity On Results Of AT (Doxorubicin Plus Docetaxel) Neoadjuvant Chemotherapy In Locally Advanced Breast Cancer PatientsStudies on the Pharmacokinetics and Pharmacodynamics of Propranolol in Hyperlipidemia
P50
Q28078880-5609987C-DB6B-40D5-A306-2CB72F78B600Q34030871-826CBB27-3DC1-424C-9E4E-717D9782BBC2Q37277642-95A71F41-7E82-4EAF-8E8D-FD915901C090Q50915584-E5B84B4D-DF8C-4CAB-B312-F142B5791472Q54394304-1C8335D7-B519-4DCE-B7A8-65639C99D050Q54947957-736AE351-7DB4-4476-B0AA-AAD7ECE4D0FEQ61546413-522827AF-A445-443C-B2D7-C8D89345ABEAQ61546453-839DB2B3-EE14-4142-A208-1AD2CA28A12A
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
ricercatrice
@it
հետազոտող
@hy
name
Violetta Sulżyc-Bielicka
@ast
Violetta Sulżyc-Bielicka
@en
Violetta Sulżyc-Bielicka
@es
Violetta Sulżyc-Bielicka
@nl
Violetta Sulżyc-Bielicka
@sl
type
label
Violetta Sulżyc-Bielicka
@ast
Violetta Sulżyc-Bielicka
@en
Violetta Sulżyc-Bielicka
@es
Violetta Sulżyc-Bielicka
@nl
Violetta Sulżyc-Bielicka
@sl
prefLabel
Violetta Sulżyc-Bielicka
@ast
Violetta Sulżyc-Bielicka
@en
Violetta Sulżyc-Bielicka
@es
Violetta Sulżyc-Bielicka
@nl
Violetta Sulżyc-Bielicka
@sl
P214
P106
P21
P213
0000 0001 1228 3763
P214
P31
P496
0000-0001-7542-1414
P735
P7859
viaf-163558911